Summary
AptaCheck is a groundbreaking platform for detecting infections pathogens in human samples: the first aptamer-based biosensor platform with lab-quality accuracy, allowing a fast, clinically accurate diagnosis. AptaCheck will overcome the drawbacks of the antibody based point-of-care (POC) devices (lower accuracy and instability). Aptacheck is equipped with a hand-held reader, which comprises a display for direct observation, a QR scanner for identifications, and WiFi for data transfer.
AptaCheck beats the state of the art:
- Cost: The disposable chip will cost the end user €10
- Time: Turnover-time is less than 15 minutes including sample handling
- Accuracy: AptaCheck will be more reliable than ELISA and comparable to PCR
- Simplicity: No special equipment or skills are needed
- Portability: The hand-held reader and biochips can be used at the point of care
- Communication: AptaCheck will be linked to electronic lab systems via wireless communication
- Action: Patients can adequately be treated; Infectious patients can immediately be isolated preventing eventual outbreaks
- Versatile: AptaCheck can easily be adapted to detection of new pathogens.
We consolidated our first-mover advantage in in-house, robust, semi-automated, cutting-edge, up-scalable industrial production process for the biochips.
AptaChek will be approved and deployed in clinical microbiological departments in hospitals. Later it will be deployed at clinics, drug manufacturing industry, etc.
With Phase II financing, AptaCheck will enter a €3.3bn market for gastroenteritis diagnostics in 2020, and produce €74.8m in cumulative revenues for FLU and 600 new jobs in FLU and the supply chain by 2024. FLU seeks funding to complete the system optimisation for pre-clinical testing and for the obligatory clinical approvals.
In parallel to this, we will secure a key strategic downstream distribution partner, and investigate new markets and applications in the diagnostics sector for the AptaCheck platform.
AptaCheck beats the state of the art:
- Cost: The disposable chip will cost the end user €10
- Time: Turnover-time is less than 15 minutes including sample handling
- Accuracy: AptaCheck will be more reliable than ELISA and comparable to PCR
- Simplicity: No special equipment or skills are needed
- Portability: The hand-held reader and biochips can be used at the point of care
- Communication: AptaCheck will be linked to electronic lab systems via wireless communication
- Action: Patients can adequately be treated; Infectious patients can immediately be isolated preventing eventual outbreaks
- Versatile: AptaCheck can easily be adapted to detection of new pathogens.
We consolidated our first-mover advantage in in-house, robust, semi-automated, cutting-edge, up-scalable industrial production process for the biochips.
AptaChek will be approved and deployed in clinical microbiological departments in hospitals. Later it will be deployed at clinics, drug manufacturing industry, etc.
With Phase II financing, AptaCheck will enter a €3.3bn market for gastroenteritis diagnostics in 2020, and produce €74.8m in cumulative revenues for FLU and 600 new jobs in FLU and the supply chain by 2024. FLU seeks funding to complete the system optimisation for pre-clinical testing and for the obligatory clinical approvals.
In parallel to this, we will secure a key strategic downstream distribution partner, and investigate new markets and applications in the diagnostics sector for the AptaCheck platform.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/783750 |
| Start date: | 01-08-2017 |
| End date: | 31-07-2019 |
| Total budget - Public funding: | 2 254 187,50 Euro - 1 577 931,00 Euro |
Cordis data
Original description
AptaCheck is a groundbreaking platform for detecting infections pathogens in human samples: the first aptamer-based biosensor platform with lab-quality accuracy, allowing a fast, clinically accurate diagnosis. AptaCheck will overcome the drawbacks of the antibody based point-of-care (POC) devices (lower accuracy and instability). Aptacheck is equipped with a hand-held reader, which comprises a display for direct observation, a QR scanner for identifications, and WiFi for data transfer.AptaCheck beats the state of the art:
- Cost: The disposable chip will cost the end user €10
- Time: Turnover-time is less than 15 minutes including sample handling
- Accuracy: AptaCheck will be more reliable than ELISA and comparable to PCR
- Simplicity: No special equipment or skills are needed
- Portability: The hand-held reader and biochips can be used at the point of care
- Communication: AptaCheck will be linked to electronic lab systems via wireless communication
- Action: Patients can adequately be treated; Infectious patients can immediately be isolated preventing eventual outbreaks
- Versatile: AptaCheck can easily be adapted to detection of new pathogens.
We consolidated our first-mover advantage in in-house, robust, semi-automated, cutting-edge, up-scalable industrial production process for the biochips.
AptaChek will be approved and deployed in clinical microbiological departments in hospitals. Later it will be deployed at clinics, drug manufacturing industry, etc.
With Phase II financing, AptaCheck will enter a €3.3bn market for gastroenteritis diagnostics in 2020, and produce €74.8m in cumulative revenues for FLU and 600 new jobs in FLU and the supply chain by 2024. FLU seeks funding to complete the system optimisation for pre-clinical testing and for the obligatory clinical approvals.
In parallel to this, we will secure a key strategic downstream distribution partner, and investigate new markets and applications in the diagnostics sector for the AptaCheck platform.
Status
CLOSEDCall topic
SMEInst-02-2016-2017Update Date
27-10-2022
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
H2020-EU.2.1.2. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies
H2020-EU.2.1.3. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials
H2020-EU.2.1.5. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing
